Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Several Factors May Help Predict Survival in Relapsed/Refractory DLBCL

Key clinical point: A retrospective study suggests several clinical and inflammatory markers have prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Major finding: A higher Glasgow Prognostic Score, derived neutrophil/lymphocyte ratio, and NCCN-International Prognostic Index were each significantly associated with poor survival.

Study details: A retrospective analysis of 242 patients with relapsed/refractory DLBCL.

Disclosures: The study was supported by the Pusan National University. The authors reported having no conflicts of interest.


Kim DY et al. Blood Res. 2019 Dec;54(4):244-52.